We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

This study is currently recruiting participants.
Verified May 2017 by Odelia Cooper, Cedars-Sinai Medical Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT00939523
First Posted: July 15, 2009
Last Update Posted: May 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Odelia Cooper, Cedars-Sinai Medical Center
  Purpose

PURPOSE

The drug Lapatinib has been shown to inhibit both epidermal growth factor receptor (EGFR) and erbB2 tyrosine kinases resulting in an effective slowing of disease progression in breast cancer. It has also been demonstrated that erbB is overexpressed in human pituitary adenomas. The investigators are therefore assessing tumor size stabilization and pituitary tumor secretory profiles during the course of a six month therapy of lapatinib. The purpose of this trial will be to estimate the activity of lapatinib in slowing the growth rate of pituitary tumors. Lapatinib is an FDA approved drug used to treat breast cancer. However, in this study, the drug will be used to treat pituitary cancer.

STUDY POPULATION

This study will recruit patients from the Pituitary Center at CSMC who are over the age of 18 that have a recurrent nonfunctioning adenoma after at least one surgical resection as well as patients with prolactinomas who are resistant to dopamine agonist therapy and patients with recurrent Cushing's disease.

PARTICIPANT'S JOURNEY THROUGH THE RESEARCH

The principal investigator (PI) or co-investigator will determine patients' potential eligibility for the study based on inclusion and exclusion criteria.

The PI or the co-investigator will then approach subjects with recurrent nonfunctioning adenomas or prolactinomas resistant to dopamine agonist therapy or recurrent Cushing's disease during a visit in the clinic office and ask if these subjects would be interested in participating in this study. If the subjects express interest, they will be given the consent form to review. They will be encouraged to review it with family, friends, and/or other physicians. The PI, co-investigators, or research nurse will be available for any questions the subjects might have. If the subjects are still interested, they will be asked to sign and return the consent form to the office and a study visit will be scheduled.

The PI, co-investigator, or member of study staff may also attempt to contact current patients by phone to assess interest in participating in the study. The purpose and overall structure of the study will be discussed with the possible participant. They will be reminded that the study is strictly voluntary and that their involvement or disinterest in the study will not affect their ongoing care. If the patient is interested they will be mailed a consent to review and will be asked to call the center to schedule an appointment to further discuss the study if they decide they are interested.

Each participant will undergo 8 visits of the course of the study. Each participant will have a baseline visit where a medical history will be taken, a physical, visual field test, electrocardiogram (ECG), echocardiogram (ECHO), and blood draw will be performed. At this point lapatinib therapy will begin and the patients will be asked to take the drug daily for the next six months. Patients will take Lapatinib 1250 mg daily (orally), which is the standardized dose used to treat breast cancer patients. Visit 2 will be 1 month after the participant has started lapatinib. At visit 2 all participants will receive a physical exam, a history will be taken, an ECG will be performed, and a blood draw will occur. Visit 3 will be 2 months after starting lapatinib. A physical exam and history will be performed along with an ECG and echocardiogram and blood draw. Visit 4 will be 3 months after starting lapatinib. A physical, history, blood draw, ECG, visual field test, and a magnetic resonance imaging (MRI) of the pituitary will be performed. Visit 5 will occur 4 months after starting lapatinib. A physical exam and history along with a blood draw and ECG and echocardiogram will occur. Visit 6 will be 5 months after starting lapatinib. A physical exam, history, ECG, and a blood draw will occur. Visit 7 will occur 6 months after the start of lapatinib. A physical exam, history, blood draw, visual field test, ECG, echocardiogram and MRI of the pituitary will occur. At this point lapatinib will be discontinued. Visit 8 will occur 1 month after visit 7 and a physical exam, history, blood draw, and ECG and and echocardiogram will occur.


Condition Intervention Phase
Pituitary Adenomas Prolactinomas Drug: Lapatinib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Resource links provided by NLM:


Further study details as provided by Odelia Cooper, Cedars-Sinai Medical Center:

Primary Outcome Measures:
  • Primary outcome in nonfunctioning adenomas: stabilization of tumor volume and mean tumor diameter on MRI. Stabilization is defined as < 2 mm change in any dimension. MRIs will be performed at baseline and at 3 and 6 months. [ Time Frame: baseline and every 3 months ]
  • Primary outcome in prolactinomas: normalization of prolactin levels. Prolactin levels will be measured at baseline and monthly. [ Time Frame: every month ]

Secondary Outcome Measures:
  • Secondary outcomes: measurement of pituitary hormones [ Time Frame: monthly ]
    In both nonfunctioning adenomas and prolactinomas, patients will have pituitary hormone lab testing.

  • Secondary outcome: visual field testing [ Time Frame: every 1-3 months ]
    Patients with preexisting visual field compromise will undergo visual field tests at visits 1-4 and 7. Patients with normal baseline visual field test will undergo visual field testing on visit 1, 4, 7.


Estimated Enrollment: 21
Study Start Date: July 2009
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lapatinib
All participants will be asked to take Lapatinib daily for a total of six months during the research study.
Drug: Lapatinib
All participants will be asked to take Lapatinib daily for six months during the research study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with nonfunctioning adenomas who have undergone at least one prior surgical resection and have demonstrated recurrence on MRI
  • Patients with prolactinomas who are resistant to dopamine agonist therapy
  • Patients with malignant pituitary tumors
  • Patients with visual field deficits and/or compression of the optic chiasm must be stable for at least 6 months

Exclusion Criteria:

  • Patients with compromised visual fields and/or compression of the optic chiasm on MRI that has not been stable for last 6 months.
  • Patients that have reduced left ventricular ejection fraction less than 50%
  • Patients with moderate to severe hepatic impairment
  • Patients that are pregnant or lactating
  • Patients under the age of 18
  • Active hepatitis
  • Known previous HIV Positive
  • Concurrent cancers
  • Life expectancy less than one year
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00939523


Contacts
Contact: Vivian Hwe 424-315-4489 hwev@cshs.org

Locations
United States, California
Cedars-Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Vivian Hwe    424-315-4489    vivian.hwe@cshs.org   
Principal Investigator: Odelia Cooper, MD         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: Roberto Salvatori, MD    410-955-3921    salvator@jhmi.edu   
Principal Investigator: Roberto Salvatori, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Karen Liebert, BSN, RN    617-726-7473    kpulaski@partners.org   
Principal Investigator: Janet Lo, MD         
Sponsors and Collaborators
Cedars-Sinai Medical Center
Investigators
Principal Investigator: Odelia Cooper, MD Cedars-Sinai Medical Center
  More Information

Responsible Party: Odelia Cooper, Principal investigator, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier: NCT00939523     History of Changes
Other Study ID Numbers: 18129
First Submitted: July 14, 2009
First Posted: July 15, 2009
Last Update Posted: May 15, 2017
Last Verified: May 2017

Keywords provided by Odelia Cooper, Cedars-Sinai Medical Center:
recurrent nonfunctioning adenoma
prolactinomas
resistant pituitary tumors
aggressive pituitary tumors
malignant pituitary adenomas

Additional relevant MeSH terms:
Adenoma
Pituitary Diseases
Pituitary Neoplasms
Prolactinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Lapatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action


To Top